Non-inferiority clinical trials: Practical issues and current regulatory perspective

Area of Science:

• Clinical Trials
• Pharmacology
• Regulatory Science

Background:

• Non-inferiority clinical trials are increasingly used to evaluate new treatments with comparable efficacy but potentially better safety profiles.
• These trials aim to demonstrate that a test product is not unacceptably worse than a reference product.
• Key considerations include assay sensitivity, non-inferiority margin selection, sample size, active-control choice, and trial analysis.

Purpose of the Study:

• To discuss the increasing use and fundamental differences of non-inferiority trials compared to superiority trials.
• To highlight practical issues in designing and conducting non-inferiority trials.
• To present US FDA recommendations on the suitability of non-inferiority designs for different infectious disease indications.

Main Methods:

• Review of non-inferiority trial principles and methodologies.
• Analysis of US FDA recommendations regarding trial designs for specific infectious diseases.
• Discussion of factors influencing the choice between non-inferiority and superiority designs.

Main Results:

• The US FDA recommends non-inferiority trials for serious infections (e.g., hospital-acquired pneumonia) where placebo-controlled data can establish an efficacy margin.
• For conditions with high spontaneous resolution rates (e.g., acute bacterial sinusitis), the US FDA advises against non-inferiority designs, recommending superiority trials instead.
• The choice of trial design depends on the indication's characteristics, including disease severity and natural resolution rates.

Conclusions:

• Non-inferiority trials are valuable for demonstrating comparable efficacy and potential advantages like improved safety.
• The US FDA's guidance emphasizes tailoring trial design to the specific clinical context and disease characteristics.
• Appropriate trial design is crucial for generating robust evidence of treatment effectiveness.